BioStem Technologies (BSEM)
Announces Retirement of 128,979,751 Shares of Common Stock and the
Issuance of Amended Series B-1 Convertible Stock
Oakland Park, FL - January 8, 2015 - InvestorsHub NewsWire
- Biostem Technologies, Inc. (BSEM),
announces that it has officially retired 128,979,751 shares of
common stock. Furthermore, the company has amended its Series B-1
shares. The retiring of the 128,979,751 common shares to treasury
reduced the total outstanding common shares by roughly 25%. We
believe that by retiring the shares, the company will be better
structured to move forward with it’s plans and goals.
Additionally, we would like to further report on the results of
the introductions from the 22nd Annual World Congress On Anti-Aging
(A4M Conference). Dr. Rafael Gonzalez, who is on the Advisory Board
of BSEM, was a keynote speaker at this event, generating much new
interest and introductions. We are striving to evaluate new ideas
and strategies to further the growth of the company. As a result of
its interaction with new people from the A4M conference, BSEM is
looking forward to incorporate new innovative treatments in the
Anti-Aging field both short and long term.
About The American Academy of Anti-Aging Medicine (A4M):
The American Academy of Anti-Aging Medicine (A4M) is a US
federally registered 501(c) 3 non-profit organization comprised of
over 26,000 members including: physicians, health practitioners,
scientists, government officials, and members of the general pubic,
representing over 110 nations.
The A4M is dedicated to the advancement of technology to detect,
prevent, and treat aging related diseases and to promote research
into methods to retard and optimize the human aging process. The
A4M is also dedicated to educating physicians, scientist, and
members of the public on biomedical sciences, breaking
technologies, and anti-aging issues.
About Biostem Technologies, Inc. (BSEM):
Biostem Technologies, Inc. is focused on helping individuals
protect and ensure their future quality of life through Adult
and/or Cord Blood Stem Cell Incubation and the practice of
regenerative medicine in the United States and the Dominican
Republic. BSEM’s mission is not only to allow patients to store
their Stem Cells for future use, but also perform patient funded
stem cell therapies ranging from sports injuries to degenerative
diseases such as MS, Arthritis, Degenerative Heart Diseases,
Diabetes and a host of experimental therapies in the brain trauma
disease sector including CTE. Our goal is to become a global leader
in establishing protocols that can be patented and utilized to heal
patients around the world.
Stem cells work as the repairmen of the body by replenishing and
regenerating damaged tissues and cells. Certain conditions have
shown marked improvement when treated with stem cells taken from
the patient's own body as well as Cord Blood stem cells.
Forward-Looking Statements ?Except for statements of historical
fact, the matters discussed in this press release are forward
looking and made pursuant to the Safe Harbor provisions of the
Private Securities Litigation Reform Act of 1995. "Forward-looking
statements" describe future expectations, plans, results, or
strategies and are generally preceded by words such as "future,"
"plan" or "planned," "expects,"”believe” or "projected." These
forward-looking statements reflect numerous assumptions and involve
a variety of risks and uncertainties, many of which are beyond the
company's control that may cause actual results to differ
materially from stated expectations. These risk factors include,
among others, limited operating history, difficulty in developing,
exploiting and protecting proprietary technologies, intense
competition and additional risks factors as discussed in reports
filed by the company with OTC Markets.
Contact:
Biostem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtech.com
Email: info@biostemtech.com
Twitter: @Biostemtech